OVERVIEW
Several commercially available forms of human amniotic membrane (HAM) and amniotic fluid can be administered by patches, topical application, or injection. Amniotic membrane and amniotic fluid are being evaluated for the treatment of a variety of conditions, including chronic full-thickness diabetic lower extremity ulcers, venous ulcers, knee osteoarthritis, plantar fasciitis, and ophthalmic conditions.

MEDICAL CRITERIA
Not applicable

PRIOR AUTHORIZATION
Not applicable

POLICY STATEMENT
BlueCHiP for Medicare and Commercial Products
Treatment of nonhealing diabetic lower-extremity ulcers using the following human amniotic membrane products (AmnioBand® Membrane, Biovance®, Epifix®, Grafix™) may be considered medically necessary.

Sutured human amniotic membrane grafts may be considered medically necessary for the treatment of the following ophthalmic indications:
- Neurotrophic keratitis
- Corneal ulcers and melts
- Pterygium repair
- Stevens-Johnson syndrome
- Persistent epithelial defects

BlueCHiP for Medicare
Sutured human amniotic membrane grafts are considered not covered for the treatment of all other ophthalmic conditions including but not limited to dry eye syndrome, burns, corneal perforation, bullous keratopathy, limbus stem cell deficiency, and after photorefractive keratectomy as the evidence is insufficient to determine the effects of the technology on health outcomes.

Human amniotic membrane without suture (eg, Prokera®, AmbioDisk™) for ophthalmic indications is not covered as the evidence is insufficient to determine the effects of the technology on health outcomes.

Injection of micronized or particulated human amniotic membrane is considered not covered for all indications, including but not limited to treatment of osteoarthritis and plantar fasciitis, as the evidence is insufficient to determine the effects of the technology on health outcomes.

Injection of human amniotic fluid is considered not covered for all indications as the evidence is insufficient to determine the effects of the technology on health outcomes.

Commercial Products
Sutured human amniotic membrane grafts are considered not medically necessary for the treatment of all other ophthalmic conditions including but not limited to dry eye syndrome, burns, corneal perforation, bullous keratopathy, limbus stem cell deficiency, and after photorefractive keratectomy as the evidence is insufficient to determine the effects of the technology on health outcomes.
Human amniotic membrane without suture (eg, Prokera®, AmbioDisk™) for ophthalmic indications is not medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes.

Injection of micronized or particulated human amniotic membrane is considered not medically necessary for all indications, including but not limited to treatment of osteoarthritis and plantar fasciitis, as the evidence is insufficient to determine the effects of the technology on health outcomes.

Injection of human amniotic fluid is considered not medically necessary for all indications as the evidence is insufficient to determine the effects of the technology on health outcomes.

**COVERAGE**

Benefits may vary between groups and contracts. Please refer to the appropriate section of the Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable surgery and not medically necessary/not covered benefits/coverage.

**BACKGROUND**

**HUMAN AMNIOTIC MEMBRANE**

Human amniotic membrane (HAM) consists of 2 conjoined layers, the amnion, and chorion, and forms the innermost lining of the amniotic sac or placenta. When prepared for use as an allograft, the membrane is harvested immediately after birth, cleaned, sterilized, and either cryopreserved or dehydrated. Many products available using amnion, chorion, amniotic fluid, and umbilical cord are being studied for the treatment of a variety of conditions, including chronic full-thickness diabetic lower-extremity ulcers, venous ulcers, knee osteoarthritis, plantar fasciitis, and ophthalmic conditions. The products are formulated either as patches, which can be applied as wound covers, or as suspensions or particulates, or connective tissue extractions, which can be injected or applied topically (see Table 1).

The fresh amniotic membrane contains collagen, fibronectin, and hyaluronic acid, along with a combination of growth factors, cytokines, and anti-inflammatory proteins such as interleukin-1 receptor antagonist. There is evidence that the tissue has anti-inflammatory, antifibroblastic, and antimicrobial properties. HAM is considered nonimmunogenic and has not been observed to cause a substantial immune response. It is believed that these properties are retained in cryopreserved HAM and dehydrated HAM products, resulting in a readily available tissue with regenerative potential. In support, 1 dehydrated HAM product has been shown to elute growth factors into saline and stimulate the migration of mesenchymal stem cells, both in vitro and in vivo.

Use of a HAM graft, which is fixated by sutures, is an established treatment for disorders of the corneal surface, including neurotrophic keratitis, corneal ulcers and melts, following pterygium repair, Stevens-Johnson syndrome, and persistent epithelial defects. Amniotic membrane products that are inserted like a contact lens have more recently been investigated for the treatment of corneal and ocular surface disorders. Amniotic membrane patches are also being evaluated for the treatment of various other conditions, including skin wounds, burns, leg ulcers, and prevention of tissue adhesion in surgical procedures. Additional indications studied in preclinical models include tendonitis, tendon repair, and nerve repair. The availability of HAM opens the possibility of regenerative medicine for an array of conditions.

**AMNIOTIC FLUID**

Amniotic fluid surrounds the fetus during pregnancy and provides protection and nourishment. In the second half of gestation, most of the fluid is a result of micturition and secretion from the respiratory tract and gastrointestinal tract of the fetus, along with urea.1 The fluid contains proteins, carbohydrates, peptides, fats, amino acids, enzymes, hormones, pigments, and fetal cells. Use of human and bovine amniotic fluid for orthopedic conditions was first reported in 1927.3 Amniotic fluid has been compared with synovial fluid, containing hyaluronan, lubricant, cholesterol, and cytokines. Injection of amniotic fluid or amniotic fluid–derived cells is currently being evaluated for the treatment of osteoarthritis and plantar fasciitis.
Diabetic Lower-Extremity Ulcers
For individuals who have nonhealing diabetic lower-extremity ulcers who receive a patch or flowable formulation of HAM (i.e., AmnioBand Membrane, Biovance, EpiFix, Grafix), the evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome. Results have shown improved outcomes compared with standard care, and outcomes that are at least as good as an established advanced wound care product.

Lower-Extremity Ulcers due to Venous Insufficiency
For individuals who have lower-extremity ulcers due to venous insufficiency who receive a patch or flowable formulation of HAM, the evidence is insufficient to determine the effects of the technology on health outcomes. Well-designed and well-conducted random controlled trials that compare HAM with the standard of care for venous insufficiency ulcers are needed.

Osteoarthritis
For individuals who have knee osteoarthritis who receive an injection of suspension or particulate formulation of HAM or amniotic fluid, the evidence is insufficient to determine the effects of the technology on health outcomes.

Plantar Fasciitis
For individuals who have plantar fasciitis who receive an injection of suspension or particulate formulation of HAM or amniotic fluid, the evidence is insufficient to determine the effects of the technology on health outcomes.

Ophthalmic Conditions
For individuals who have neurotrophic keratitis, corneal ulcers and melts, pterygium repair, Stevens-Johnson syndrome, or persistent epithelial defects who receive sutured HAM graft, the evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have ophthalmic disorders other than neurotrophic keratitis, corneal ulcers and melts, pterygium repair, Stevens-Johnson syndrome, or persistent epithelial defects who receive sutured HAM graft, the evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have ophthalmic conditions who receive HAM without suture, the evidence is insufficient to determine the effects of the technology on health outcomes.

CODING
BlueCHiP for Medicare and Commercial Products
The following HCPCS codes are considered medically necessary when filed with the ICD-10 diagnosis codes listed below.
Q4131 EpiFix or Epicord, per square centimeter
Q4132 Grafix core and GrafixPL core, per square centimeter
Q4133 Grafix prime and GrafixPL prime, per square centimeter
Q4137 Amnioexcel or BioDExCel, per square centimeter
Q4138 Biodfence Dryflex, per square centimeter
Q4139 AmnioMatrix or BioDMatrix, injectable, 1 cc
Q4140 Biodfence, per square centimeter
Q4145 EpiFix, injectable, 1 mg
Q4148 Neox cord 1k, Neox cord RT, or Clarix cord 1K, per square centimeter
Q4150 AlloWrap DS or dry, per square centimeter
Q4151 AmnioBand or Guardian, per square centimeter
Q4153 Dermavest and Plurivest, per square centimeter
Q4154 Biovance, per square centimeter
Q4155 Neoxflo or Clarixflo, 1 mg
Q4156 Neox 100 or Clarix 100, per square centimeter
Q4157 Revitalon, per square centimeter
Q4159 Affinity, per square centimeter
Q4160 NuShield, per square centimeter
Q4162 WoundEx Flow, BioSkin Flow, 0.5 cc
Q4163 WoundEx, BioSkin, per square centimeter
Q4168 Amnioband, 1 mg
Q4169 Artacent wound, per square centimeter
Q4170 Cygnus, per square centimeter
Q4171 Interfyl, 1 mg
Q4173 PalinGen or PalinGen XPlus, per square centimeter
Q4174 PalinGen or ProMatrX, 0.36 mg per 0.25 cc

ICD-10 Diagnosis Codes that may support medical necessity:

<table>
<thead>
<tr>
<th>Code 1</th>
<th>Code 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>E08.621</td>
<td>H11.001-H11.069</td>
</tr>
<tr>
<td>E09.621-E09.622</td>
<td>H16.001-H16.079</td>
</tr>
<tr>
<td>E10.621-E10.622</td>
<td>H16.231-H16.239</td>
</tr>
<tr>
<td>E11.621-E11.622</td>
<td>H18.831-H18.839</td>
</tr>
<tr>
<td>E13.621-E13.622</td>
<td>L51.1</td>
</tr>
</tbody>
</table>

RELATED POLICIES
Not applicable

PUBLISHED
Provider Update, July 2018

REFERENCES
This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.